Skip to main content
Figure 4 | Respiratory Research

Figure 4

From: Efficacy and safety of fixed-dose combinations of aclidinium bromide/formoterol fumarate: the 24-week, randomized, placebo-controlled AUGMENT COPD study

Figure 4

Mean changes from baseline in morning predose (trough) FEV 1 (A) at week 24 (coprimary endpoint) and (B) over time across duration of study. Analyses were based on a mixed-model for repeated measures. *p< 0.05 versus placebo; ‡p< 0.05 versus formoterol and placebo; §p< 0.05 versus aclidinium, formoterol, and placebo. ACL400/FOR12 FDC, fixed-dose combination of aclidinium 400μg and formoterol 12μg; ACL400/FOR6 FDC, fixed-dose combination of aclidinium 400μg and formoterol 6μg; FEV1, forced expiratory volume in 1 second; LS, least squares.

Back to article page

Respiratory Research

ISSN: 1465-993X

Contact us